Key Takeaways
- Licensed prescribing criteria for Wegovy and Mounjaro include adults with a BMI of 30+ (obesity), or a BMI of 27+ alongside at least one weight-related health condition.
- Qualifying weight-related comorbidities include hypertension, prediabetes or type 2 diabetes, dyslipidemia (high cholesterol/triglycerides), obstructive sleep apnea, PCOS, and cardiovascular disease.
- Clinical guidelines apply a 2.5 kg/m² lower BMI threshold for South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean adults due to earlier cardiometabolic risk.
- Publicly funded health-system cohorts often restrict access to BMI 35–40+ with multiple comorbidities, which is why many medically eligible patients choose regulated telehealth care.
Search online for “what BMI do you need for Wegovy or Mounjaro?” and you’ll see numbers ranging anywhere from 27 to 40+. The reason websites appear to contradict one another is that regulatory drug licensing criteria (used by licensed telehealth and private clinicians) are much broader than rationed public-sector reimbursement tiers.
Licensed Clinical Eligibility vs. Public Rationing Tiers
| Criterion | Licensed Medical Eligibility (Telehealth / Private Rx) | Restricted Public-System Tiers (e.g., NHS Specialist Cohorts) |
|---|---|---|
| Standard BMI threshold (no comorbidities) | BMI ≥ 30 kg/m² | Generally not covered without comorbidities |
| BMI threshold with ≥1 weight-related condition | BMI ≥ 27 kg/m² | Wegovy: BMI ≥35 + comorbidity; Mounjaro phased cohorts: BMI 35–40+ with 3–4 comorbidities |
| Ethnicity-adjusted BMI reduction | Up to 2.5 BMI points lower per clinical risk assessment | 2.5 BMI points lower (e.g., 32.5 instead of 35) |
| Specialist clinic referral required? | No — direct clinician assessment & verification | Yes — multi-month specialist or phased primary-care queue |
To put those numbers in everyday terms: for an adult standing 5’5″ (165 cm), a BMI of 30 equals roughly 180 lbs (81.6 kg), while a BMI of 27 equals roughly 162 lbs (73.5 kg).
Why Ethnic Background Lowers Cardiometabolic BMI Cutoffs
Large epidemiological cohorts show that adults of South Asian, East and Southeast Asian, Middle Eastern, Black African, and Caribbean heritage develop visceral organ fat, insulin resistance, type 2 diabetes, and coronary risk at a 2.5 kg/m² lower BMI than White European populations. Clinical guidelines (such as NICE NG246 and TA1026) incorporate this adjustment so patients aren’t denied preventive metabolic care simply because standard BMI charts were calibrated decades ago on narrow populations.
What Happens During a Regulated Online Weight Care Assessment?
- BMI & anthropometric verification: Submitting accurate height, weight, and required identity/body verification.
- Comorbidity & medication screen: Checking blood pressure, glycemic history, lipid labs, and screening out contraindications (pregnancy, breastfeeding, history of pancreatitis, or personal/family history of medullary thyroid cancer or MEN2).
- Personalized titration plan: Selecting the safest starting dose of Wegovy, Mounjaro, or an oral GLP-1 with ongoing clinician follow-up.
References
- NICE Technology Appraisal TA1026. Tirzepatide for managing overweight and obesity. 2024–2026.
- NICE Guideline NG246. Overweight and obesity management. 2025.
Related Clinical Guides
Your personalizedweight care plan
Clinician-prescribed GLP-1 & metabolic care, 100% online.